






# Lower co-pays and savings may be available with **Mitigare®** & **Generic Colchicine Capsules**

**Colchicine Capsules and tablets are NOT AB-rated or substitutable**

-  **Co-pays for eligible customers may be as little as \$0 for the first fill\*; as low as \$5 for refills\***
-  **True Blue Savings—The ONLY co-pay program that helps eligible patients save on Generic Colchicine Capsules and Mitigare®\***
-  **Mitigare® and Generic Colchicine Capsules are covered by more than 90% of insurance plans, including Humana†**

\* For all eligible patients 18 years or older who are legal residents of the United States or Puerto Rico. Only eligible patients pay as little as \$0 for the first 30 days and as little as \$5 on refills. Please see mitigate.com for complete Terms and Conditions. Maximum savings of \$65 on the first fill and \$50 on refills.

† Managed Markets Insight & Technology, LLC database and formulary status as of January 2021.

## Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare® for acute treatment of gout flares during prophylaxis have not been studied. Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

## Important Safety Information

- Colchicine 0.6mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
- Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
- Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia and aplastic anemia have been reported with colchicine used in therapeutic doses.
- Monitor for toxicity and, if present, consider temporary interruption or discontinuation of colchicine.
- Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.

- Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
- The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting and abdominal pain.

## Please see accompanying Full Prescribing Information and Medication Guide.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228  
Mitigare® is a registered trademark of Hikma Pharmaceuticals USA Inc.  
©2021 Hikma Pharmaceuticals USA Inc. All rights reserved.  
For US Healthcare Professionals only.

WW00803v3



**hikma.**



# Regularly replenish your inventory with Mitigare® and Generic Colchicine Capsules

| Product                  | NDC#          | Bottle   | ABC      | Cardinal | McKesson | Morris & Dickson |
|--------------------------|---------------|----------|----------|----------|----------|------------------|
| Mitigare® 0.6mg Capsules | 59467-0318-30 | 30 ct    | 10218162 | 5517263  | 3957487  | 408922           |
| Mitigare® 0.6mg Capsules | 59467-0318-01 | 100 ct   | 10160301 | 5197579  | 3506151  | 882332           |
| Mitigare® 0.6mg Capsules | 59467-0318-10 | 1,000 ct | 10160300 | 5197595  | 3506177  | 597385           |

| Product                   | NDC#          | Bottle   | ABC      | Cardinal | HD Smith | McKesson | Morris & Dickson |
|---------------------------|---------------|----------|----------|----------|----------|----------|------------------|
| Colchicine 0.6mg Capsules | 00143-3018-30 | 30 ct    | 10189411 | 5484795  | 5729876  | 3930484  | 756080           |
| Colchicine 0.6mg Capsules | 00143-3018-01 | 100 ct   | 10144830 | 5052949  | 5162474  | 3293446  | 200048           |
| Colchicine 0.6mg Capsules | 00143-3018-10 | 1,000 ct | 10144831 |          | 5162482  | 3293412  |                  |

## Start providing True Blue Savings today

**Pharmacists:** Use the **Universal True Blue Savings Card** to help your eligible customers get their first 30 days of Mitigare® (Colchicine) 0.6mg Capsules or Generic Colchicine Capsules for as little as **\$0\*** and refills for as low as **\$5.\***

- The card may be used for any eligible patient with a **Mitigare® or Generic Colchicine Capsules prescription** who does not have their own True Blue Savings Card.
- This savings card may be used to help an **unlimited** number of eligible customers save.
- If you have questions or need additional assistance, please call **1-877-259-6893**.

**Universal True Blue Savings Card**



Mitigare®  
(colchicine) 0.6mg capsules

Pay as little as

**\$0\*** first 30 days  
& **\$5\*** refills



**For Mitigare® (Colchicine) 0.6mg Capsules or Generic Colchicine Capsules.**

RxBIN#:  
PCN:  
Group#:  
ID#:  
Expiration Date:  
Generic Colchicine Capsules:  
Brand Mitigare:

hikma.

\*Maximum savings of \$65 on first fill, \$50 on refills. Must meet eligibility requirements. See reverse side for complete Terms & Conditions.  
There is no limit on the number of eligible customers this card may be used to assist.

**To Obtain a Card Go to:**  
[mitigare.com/universal-card](http://mitigare.com/universal-card)  
or contact your Hikma Sales Representative.